86. Pulmonary arterial hypertension Clinical trials / Disease details

Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

123 trials found

diseases per page:

Showing 1 to 10 of 123 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05147805 (ClinicalTrials.gov)	March 31, 2022	24/11/2021	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of TreprostinilPalmitil Inhalation Pow ...	A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy ...	Pulmonary Arterial Hypertension	Drug: Treprostinil Palmitil;Drug: Placebo	Insmed Incorporated	NULL	Recruiting	18 Years	75 Years	All	99	Phase 2	United States
2	EUCTR2021-004002-21-AT (EUCTR)	26/11/2021	06/09/2021	A non-randomized, single-center, open, two-period study with paired design to compare measured stead ...	A single center, open-label, two-period, non-randomized, paired-design study to compare steady-state ...	pulmonary arterial hypertension MedDRA version: 21.1;Level: PT;Classification code 10064911;Term: Pu ...	Product Name: 20 mg/ml Treprostinil INN or Proposed INN: treprostinil sodium Other descriptive name: TR ...	AOP Orphan Pharmaceuticals GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	16	Phase 2	Austria
3	NCT04791514 (ClinicalTrials.gov)	May 31, 2021	8/3/2021	Open Label Study of TreprostinilPalmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension ...	An Open-Label Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of TreprostinilPalm ...	Pulmonary Arterial Hypertension	Drug: Treprostinil Palmitil	Insmed Incorporated	NULL	Recruiting	18 Years	N/A	All	10	Phase 2	United States
4	NCT03833323 (ClinicalTrials.gov)	August 1, 2020	5/2/2019	Implantable System for Remodulin Post-Approval Study	Implantable System for Remodulin Post-Approval Study	Pulmonary Arterial Hypertension	Combination Product: Implantable System for Remodulin (treprostinil)	Medtronic Cardiac Rhythm and Heart Failure	United Therapeutics	Withdrawn	22 Years	N/A	All	0		NULL
5	NCT04309838 (ClinicalTrials.gov)	March 2020	20/2/2020	Observation Study With Implantable Medication Pump for Intravenous TreprostinilTherapy in Patients W ...	LENUS Pro® Study (LPS-II) - Observation Study With Implantable Medication Pump for Intravenous REMOD ...	Pulmonary Arterial Hypertension;PAH	Combination Product: Treprostinil via implanted pump	University Medicine Greifswald	OMT GmbH & Co. KG	Not yet recruiting	18 Years	N/A	All	30		Germany
6	NCT03884465 (ClinicalTrials.gov)	November 11, 2019	4/3/2019	Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil	A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Res ...	Pulmonary Arterial Hypertension	Drug: Inhaled dry powder treprostinil (LIQ861)	Liquidia Technologies, Inc.	FGK Clinical Research GmbH	Recruiting	18 Years	N/A	All	32	Phase 2	France;Germany
7	NCT03950739 (ClinicalTrials.gov)	September 17, 2019	9/5/2019	Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Curr ...	An Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreprostinilInhalation Powd ...	Pulmonary Arterial Hypertension	Drug: Treprostinil Inhalation Powder	United Therapeutics	NULL	Active, not recruiting	18 Years	N/A	All	51	Phase 1	United States
8	NCT03992755 (ClinicalTrials.gov)	July 18, 2019	5/6/2019	Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inh ...	A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Saf ...	Primary Pulmonary Hypertension	Drug: LIQ861 Inhaled Treprostinil	Liquidia Technologies, Inc.	Nuventra, Inc.	Active, not recruiting	18 Years	N/A	All	92	Phase 3	United States
9	NCT03835676 (ClinicalTrials.gov)	May 1, 2019	6/2/2019	Effects of Treprostinilon Right Ventricular Structure and Function in Patients With Pulmonary Arteri ...	Effects of Treprostinilon Right Ventricular Structure and Function in Patients With Pulmonary Arteri ...	Pulmonary Hypertension	Drug: Treprostinil	Magdi H. Yacoub	NULL	Recruiting	18 Years	N/A	All	30	Phase 4	Egypt
10	NCT04062565 (ClinicalTrials.gov)	March 25, 2019	29/3/2019	Trial to Evaluate Parenteral Treprostiniland Riociguat on Right Ventriculo-vascular Coupling and Mor ...	A Prospective Trial to Evaluate Up-front Parenteral Treprostiniland Riociguat on Right Ventriculo-va ...	Pulmonary Arterial Hypertension	Drug: Treprostinil Injectable Product;Drug: Riociguat Pill	University of Arizona	NULL	Recruiting	18 Years	N/A	All	20	Phase 3	United States

First Previous1 2 3 4 5…13Next Last